North Carolina life sciences companies, startups and academic institutions are tackling some of the world's greatest ...

The Central California Blood Center has a new CEO to spearhead the nonprofit's mission of providing blood to area hospitals.

Tevogen Bio is driven by a team of highly experienced industry leaders and distinguished scientists with drug development and global product launch experience. Tevogen Bio’s leadership believes that ...

Jefferies analyst James Vane maintained a Buy rating on Sartorius Stedim Biotech (0RG8 – Research Report) today and set a price target of €269.00. The company’s shares closed yesterday at ...

A requisite majority of H-class shareholders did not approve the buyout, the companies said. "The proposed privatisation of the Company (Henlius) will not proceed and the listing of the H Shares ...

Primarily, Ascentage hopes to leverage the IPO proceeds to advance its pipeline. Around $50 million to $60 million, for instance, will help the biotech pursue approval for its BCL-2 blocker ...

The biotech firm's mRNA-1018 candidate posted positive results in a Phase 1/2 study launched in 2023. Moderna plans to move mRNA-1018 to a Phase 3 trial. Shares of Moderna (MRNA) took off Tuesday ...

In 2019, Stan­ford Uni­ver­si­ty pro­fes­sor Irv Weiss­man and a col­league pub­lished a pa­per that rep­re­sent­ed a new way to tar­get some ag­gres­sive can­cers.

Odyssey Therapeutics and Sionna Therapeutics have filed IPO paperwork, swelling the pack of startups that will provide an early look at how receptive public investors could be to biotech listings ...

Prolium was set up by RTW in 2024. Last year also saw the New York-based investment fund involved in the launch of obesity biotech Kailera Therapeutics, which RTW said at the time was the fourth ...

Of course, some criticize these modern logos as being copy-and-paste, minimalist and unoriginal. Those yearn to return to the unique logos of the 1990s and early 2000s, where the NFL used elements ...